stella
beta
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC — Stella
Recruiting
Back to Head and Neck Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai
View full record on ClinicalTrials.gov